ATE182080T1 - Dosierungsform die ein antigen und eine salzform eines organischen säurederivats eines sterols enthält - Google Patents

Dosierungsform die ein antigen und eine salzform eines organischen säurederivats eines sterols enthält

Info

Publication number: ATE182080T1
Authority: AT; Austria
Prior art keywords: antigen; sterol; organic acid; acid derivative; dosage form
Prior art date: 1988-08-25

Application number

AT94201844T

Other languages

English (en)

Inventor

Mircea C Popescu

Marie S Recine

Carl L Alving

Leonard F Estis

Lynn D Keyes

Andrew S Janoff

Original Assignee

Liposome Co Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-08-25

Filing date

1989-08-25

Publication date

1999-07-15

1989-08-25 Application filed by Liposome Co Inc filed Critical Liposome Co Inc

1999-07-15 Application granted granted Critical

1999-07-15 Publication of ATE182080T1 publication Critical patent/ATE182080T1/de

Links

239000000427 antigen Substances 0.000 title abstract 7
102000036639 antigens Human genes 0.000 title abstract 7
108091007433 antigens Proteins 0.000 title abstract 7
239000002552 dosage form Substances 0.000 title abstract 4
229930182558 Sterol Natural products 0.000 title abstract 3
150000007524 organic acids Chemical class 0.000 title abstract 3
150000003432 sterols Chemical class 0.000 title abstract 3
235000003702 sterols Nutrition 0.000 title abstract 3
150000003839 salts Chemical group 0.000 title abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 4
230000003053 immunization Effects 0.000 abstract 4
238000002649 immunization Methods 0.000 abstract 3
239000002502 liposome Substances 0.000 abstract 3
235000012000 cholesterol Nutrition 0.000 abstract 2
230000028993 immune response Effects 0.000 abstract 2
206010022000 influenza Diseases 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
108010004032 Bromelains Proteins 0.000 abstract 1
101710154606 Hemagglutinin Proteins 0.000 abstract 1
101710093908 Outer capsid protein VP4 Proteins 0.000 abstract 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 abstract 1
239000004365 Protease Substances 0.000 abstract 1
101710176177 Protein A56 Proteins 0.000 abstract 1
229940024546 aluminum hydroxide gel Drugs 0.000 abstract 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 abstract 1
235000019835 bromelain Nutrition 0.000 abstract 1
239000012634 fragment Substances 0.000 abstract 1
239000000185 hemagglutinin Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Immunology (AREA)
Mycology (AREA)
Microbiology (AREA)
Virology (AREA)
Oncology (AREA)
Dispersion Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Manufacturing Of Micro-Capsules (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT94201844T 1988-08-25 1989-08-25 Dosierungsform die ein antigen und eine salzform eines organischen säurederivats eines sterols enthält ATE182080T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US23670288A	1988-08-25	1988-08-25
US23670188A	1988-08-25	1988-08-25
US39777789A	1989-08-23	1989-08-23

Publications (1)

Publication Number	Publication Date
ATE182080T1 true ATE182080T1 (de)	1999-07-15

Family

ID=27398905

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT89402343T ATE119037T1 (de)	1988-08-25	1989-08-25	Influenzaimpfstoff und adjuvanten.
AT94201844T ATE182080T1 (de)	1988-08-25	1989-08-25	Dosierungsform die ein antigen und eine salzform eines organischen säurederivats eines sterols enthält

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT89402343T ATE119037T1 (de)	1988-08-25	1989-08-25	Influenzaimpfstoff und adjuvanten.

Country Status (9)

Country	Link
EP (2)	EP0356339B1 (de)
JP (1)	JPH04500203A (de)
AT (2)	ATE119037T1 (de)
AU (2)	AU627226B2 (de)
CA (1)	CA1337332C (de)
DE (2)	DE68921389T2 (de)
ES (2)	ES2069600T3 (de)
GR (1)	GR3031244T3 (de)
NZ (2)	NZ230423A (de)

Families Citing this family (114)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5985318A (en) *	1990-08-24	1999-11-16	Burroughs Wellcome Co.	Fusogenic liposomes that are free of active neuraminidase
GB9018690D0 (en) *	1990-08-24	1990-10-10	Wellcome Found	Vaccines
AU655823B2 (en) *	1991-05-08	1995-01-12	Crucell Switzerland Ag	Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
US5879685A (en) *	1991-05-08	1999-03-09	Schweiz, Serum- & Impfinstitut Bern	Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
AU5420494A (en) *	1992-11-02	1994-05-24	Yves Claude Nicolau	Method of reducing multidrug resistance in cells and tissues
WO1994019013A1 (en) *	1993-02-19	1994-09-01	Smithkline Beecham Corporation	Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a
CA2183435C (en) *	1994-02-24	2008-05-13	Craig D. Wright	Vaccines containing paucilamellar lipid vesicles as immunological adjuvants
FR2726764B1 (fr) *	1994-11-14	1997-01-31	Pasteur Merieux Serums Vacc	Adjuvant pour composition vaccinale
US5919480A (en) *	1996-06-24	1999-07-06	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Liposomal influenza vaccine composition and method
CN1809380B (zh)	2002-10-11	2010-05-12	启龙有限公司	广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
ES2461350T3 (es)	2003-01-30	2014-05-19	Novartis Ag	Vacunas inyectables contra múltiples serogrupos de meningococos
GB0323103D0 (en)	2003-10-02	2003-11-05	Chiron Srl	De-acetylated saccharides
NZ546430A (en)	2003-10-02	2009-04-30	Novartis Vaccines & Diagnostic	Liquid vaccines for multiple meningococcal serogroups
DE202005022108U1 (de)	2004-03-09	2013-11-12	Novartis Vaccines And Diagnostics, Inc.	Influenza-Virus-Impfstoffe
GB0409745D0 (en)	2004-04-30	2004-06-09	Chiron Srl	Compositions including unconjugated carrier proteins
GB0500787D0 (en)	2005-01-14	2005-02-23	Chiron Srl	Integration of meningococcal conjugate vaccination
US9402915B2 (en)	2004-04-30	2016-08-02	Glaxosmithkline Biologicals Sa	Integration of meningococcal conjugate vaccination
GB0410866D0 (en)	2004-05-14	2004-06-16	Chiron Srl	Haemophilius influenzae
ES2647491T3 (es)	2004-05-21	2017-12-21	Novartis Vaccines And Diagnostics, Inc.	Vectores del alfavirus para las vacunas del virus de la gripe
US20060165716A1 (en)	2004-07-29	2006-07-27	Telford John L	Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en)	2004-10-29	2004-12-01	Chiron Srl	Immunogenic bacterial vesicles with outer membrane proteins
GB0502095D0 (en)	2005-02-01	2005-03-09	Chiron Srl	Conjugation of streptococcal capsular saccharides
SI2351772T1 (sl)	2005-02-18	2016-11-30	Glaxosmithkline Biologicals Sa	Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
JP2008530245A (ja)	2005-02-18	2008-08-07	ノバルティスヴァクシンズアンドダイアグノスティクス，インコーポレイテッド	尿路病原性菌株由来の抗原
CA2626253A1 (en)	2005-10-18	2007-04-26	Novartis Vaccines And Diagnostics, Inc.	Mucosal and systemic immunizations with alphavirus replicon particles
PL2368572T3 (pl)	2005-11-04	2020-11-16	Seqirus UK Limited	Szczepionki z adjuwantem z niewirionowymi antygenami otrzymane z wirusów grypy hodowanych w hodowli komórkowej
AU2006335256B2 (en)	2005-11-22	2012-10-18	Novartis Vaccines And Diagnostics, Inc.	Norovirus and sapovirus antigens
GB0524066D0 (en)	2005-11-25	2006-01-04	Chiron Srl	741 ii
BR122019013216B8 (pt)	2006-01-27	2021-07-27	Seqirus Uk Ltd	ensaio imunológico para análise de uma vacina contra influenza
EP2007765B1 (de)	2006-03-23	2012-06-27	Novartis AG	Immunstimulierende verbindungen
WO2007109813A1 (en)	2006-03-23	2007-09-27	Novartis Ag	Imidazoquinoxaline compounds as immunomodulators
JP2009534303A (ja)	2006-03-24	2009-09-24	ノバルティスヴァクシンズアンドダイアグノスティクスゲーエムベーハーアンドカンパニーカーゲー	冷蔵しないインフルエンザワクチンの保存
US20100285062A1 (en)	2006-03-31	2010-11-11	Novartis Ag	Combined mucosal and parenteral immunization against hiv
ATE522541T1 (de)	2006-06-09	2011-09-15	Novartis Ag	Bakterielle adhäsine konformere
ES2401484T3 (es) *	2006-06-15	2013-04-22	Novartis Ag	Régimen de vacunación contra la gripe multidosis ahorrador de adyuvantes
GB0614460D0 (en)	2006-07-20	2006-08-30	Novartis Ag	Vaccines
EP2586790A3 (de)	2006-08-16	2013-08-14	Novartis AG	Immunogene von uropathogenen Escherichia coli
EP3456348B1 (de)	2006-09-11	2025-03-26	Seqirus UK Limited	Herstellung von influenza-virus-impfstoffen ohne verwendung von eiern
PL2121011T3 (pl)	2006-12-06	2014-10-31	Novartis Ag	Szczepionki zawierające antygeny czterech szczepów wirusa grypy
GB0700562D0 (en)	2007-01-11	2007-02-21	Novartis Vaccines & Diagnostic	Modified Saccharides
CN101784283A (zh)	2007-06-27	2010-07-21	诺华有限公司	低添加流感疫苗
GB0713880D0 (en)	2007-07-17	2007-08-29	Novartis Ag	Conjugate purification
GB0714963D0 (en)	2007-08-01	2007-09-12	Novartis Ag	Compositions comprising antigens
CA2699513C (en)	2007-09-12	2018-03-13	Novartis Ag	Gas57 mutant antigens and gas57 antibodies
GB0810305D0 (en)	2008-06-05	2008-07-09	Novartis Ag	Influenza vaccination
GB0818453D0 (en)	2008-10-08	2008-11-12	Novartis Ag	Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
BRPI0821240B8 (pt)	2007-12-21	2022-10-04	Novartis Ag	formas mutantes de estreptolisina o
EP2886551A3 (de)	2008-02-21	2015-09-23	Novartis AG	Meningokokken-FHBP-Polypeptide
EP2268309B1 (de)	2008-03-18	2015-01-21	Novartis AG	Verbesserungen der herstellung von grippevirus-impstoff-antigenen
CN102481349B (zh)	2009-01-12	2014-10-15	诺华股份有限公司	抗革兰氏阳性细菌疫苗中的Cna_B结构域
CN102438650A (zh)	2009-03-06	2012-05-02	诺华有限公司	衣原体抗原
NZ612315A (en)	2009-04-14	2014-10-31	Novartis Ag	Compositions for immunising against staphylococcus aureus
EP2442826B1 (de)	2009-06-15	2015-07-08	National University of Singapore	Influenzaimpfstoff, zusammensetzung und seine verwendung
ES2662716T3 (es)	2009-07-07	2018-04-09	Glaxosmithkline Biologicals Sa	Inmunógenos conservados de Escherichia coli
TW201116294A (en)	2009-07-15	2011-05-16	Novartis Ag	RSV F protein compositions and methods for making same
SI2464658T1 (sl)	2009-07-16	2015-02-27	Novartis Ag	Detoksificirani imunogeni escherichie coli
JP2013502918A (ja)	2009-08-27	2013-01-31	ノバルティスアーゲー	髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド
WO2011030218A1 (en)	2009-09-10	2011-03-17	Novartis Ag	Combination vaccines against respiratory tract diseases
GB0917003D0 (en)	2009-09-28	2009-11-11	Novartis Vaccines Inst For Global Health Srl	Purification of bacterial vesicles
GB0917002D0 (en)	2009-09-28	2009-11-11	Novartis Vaccines Inst For Global Health Srl	Improved shigella blebs
EP2493510B1 (de)	2009-09-30	2020-07-08	GlaxoSmithKline Biologicals SA	Konjugation von kapselförmigen polysacchariden typ 5 und typ 8 aus staphylococcus aureus
US20130022639A1 (en)	2009-09-30	2013-01-24	Novartis Ag	Expression of meningococcal fhbp polypeptides
GB0918392D0 (en)	2009-10-20	2009-12-02	Novartis Ag	Diagnostic and therapeutic methods
BR112012010531A2 (pt)	2009-10-27	2019-09-24	Novartis Ag	"polipeptídeos de modificação meningocócica fhbp"
GB0919690D0 (en)	2009-11-10	2009-12-23	Guy S And St Thomas S Nhs Foun	compositions for immunising against staphylococcus aureus
US9173954B2 (en)	2009-12-30	2015-11-03	Glaxosmithkline Biologicals Sa	Polysaccharide immunogens conjugated to E. coli carrier proteins
GB201003333D0 (en)	2010-02-26	2010-04-14	Novartis Ag	Immunogenic proteins and compositions
GB201005625D0 (en)	2010-04-01	2010-05-19	Novartis Ag	Immunogenic proteins and compositions
JP2013529894A (ja)	2010-04-07	2013-07-25	ノバルティスアーゲー	パルボウイルスｂ１９のウイルス様粒子を生成するための方法
CA2796314A1 (en)	2010-04-13	2011-10-20	Novartis Ag	Benzonapthyridine compositions and uses thereof
CN102933267B (zh)	2010-05-28	2015-05-27	泰特里斯在线公司	交互式混合异步计算机游戏基础结构
GB201009861D0 (en)	2010-06-11	2010-07-21	Novartis Ag	OMV vaccines
US9192661B2 (en)	2010-07-06	2015-11-24	Novartis Ag	Delivery of self-replicating RNA using biodegradable polymer particles
CA2804501C (en)	2010-07-06	2021-01-26	Novartis Ag	Noro virus derived immunogenic compositions and methods
GB201101665D0 (en)	2011-01-31	2011-03-16	Novartis Ag	Immunogenic compositions
GB201017519D0 (en)	2010-10-15	2010-12-01	Novartis Vaccines Inst For Global Health S R L	Vaccines
CN102000332B (zh) *	2010-11-16	2012-07-04	南京农业大学	一种用于鸭禽流感口服黏膜免疫的复合佐剂
WO2012072769A1 (en)	2010-12-01	2012-06-07	Novartis Ag	Pneumococcal rrgb epitopes and clade combinations
WO2012085668A2 (en)	2010-12-24	2012-06-28	Novartis Ag	Compounds
EP4144368B1 (de)	2011-01-26	2025-02-26	GlaxoSmithKline Biologicals S.A.	Rsv-immunisierungstherapie
CN103842374A (zh)	2011-05-13	2014-06-04	诺华股份有限公司	融合前的rsv f抗原
EP3854413A1 (de)	2011-07-06	2021-07-28	GlaxoSmithKline Biologicals SA	Immunogene kombinationszusammensetzungen und ihre verwendung
CA2841047A1 (en)	2011-07-06	2013-01-10	Novartis Ag	Immunogenic compositions and uses thereof
EP2729178A1 (de)	2011-07-08	2014-05-14	Novartis AG	Tyrosinverbindungsverfahren
ES2687129T3 (es)	2011-07-25	2018-10-23	Glaxosmithkline Biologicals Sa	Composiciones y métodos para evaluar la inmunogenicidad funcional de vacunas contra parvovirus
GB201114923D0 (en)	2011-08-30	2011-10-12	Novartis Ag	Immunogenic proteins and compositions
EP2755994A2 (de)	2011-09-14	2014-07-23	Novartis AG	Impfstoffkombination gegen escherichia coli
EP2755683B1 (de)	2011-09-14	2019-04-03	GlaxoSmithKline Biologicals SA	Verfahren zur herstellung von saccharidprotein-glykokonjugaten
WO2013068949A1 (en)	2011-11-07	2013-05-16	Novartis Ag	Carrier molecule comprising a spr0096 and a spr2021 antigen
EP2788022B1 (de)	2011-12-08	2018-10-31	GlaxoSmithKline Biologicals SA	Auf clostridium difficile-toxin basierender impfstoff
WO2013108272A2 (en)	2012-01-20	2013-07-25	International Centre For Genetic Engineering And Biotechnology	Blood stage malaria vaccine
WO2013124473A1 (en)	2012-02-24	2013-08-29	Novartis Ag	Pilus proteins and compositions
CN108671228A (zh)	2012-04-26	2018-10-19	诺华股份有限公司	抗原和抗原组合
US10279026B2 (en)	2012-04-26	2019-05-07	Glaxosmithkline Biologicals Sa	Antigens and antigen combinations
RU2014151567A (ru)	2012-05-22	2016-07-10	Новартис Аг	Конъюгат менингококка серогруппы х
US20150140068A1 (en)	2012-07-06	2015-05-21	Novartis Ag	Immunogenic compositions and uses thereof
RU2662970C2 (ru)	2012-09-18	2018-07-31	Новартис Аг	Везикулы наружной мембраны
CA2885625A1 (en)	2012-10-02	2014-04-10	Glaxosmithkline Biologicals S.A.	Nonlinear saccharide conjugates
AR092896A1 (es)	2012-10-03	2015-05-06	Novartis Ag	Composiciones inmunogenicas
EP3052121B1 (de) *	2013-10-02	2023-02-22	The Board of Trustees of the Leland Stanford Junior University	Wnt-zusammensetzungen und verfahren zur reinigung
WO2015130584A2 (en)	2014-02-25	2015-09-03	Merck Sharp & Dohme Corp.	Lipid nanoparticle vaccine adjuvants and antigen delivery systems
CN104535017B (zh) *	2014-12-19	2017-11-21	合肥市百胜科技发展股份有限公司	在线轮廓测量装置
IL246378A0 (en)	2016-06-21	2016-11-30	Technion Res & Dev Foundation	A hybrid matrix of polymers that adhere to the mucosa and a lipidic drug release system for the treatment of oral cancer
US20190314486A1 (en) *	2016-10-21	2019-10-17	Merck Sharp & Dohme Corp.	Influenza hemagglutinin protein vaccines
WO2019145950A1 (en) *	2018-01-23	2019-08-01	Technion Research & Development Foundation Limited	Collagenase loaded liposomes for enhancing drug delivery
US20210220462A1 (en)	2018-08-23	2021-07-22	Glaxosmithkline Biologicals Sa	Immunogenic proteins and compositions
WO2021169673A1 (en)	2020-02-26	2021-09-02	Versitech Limited	Pd-1-based vaccines against coronavirus infection
EP4333868A1 (de)	2021-05-04	2024-03-13	King Abdullah University Of Science And Technology	Immunogene zusammensetzungen von mutiertem sars-cov-2 n-protein und gen und verfahren zur verwendung davon
US20250302943A1 (en)	2021-11-05	2025-10-02	King Abdullah University Of Science And Technology	Re-focusing protein booster immunization compositions and methods of use thereof
WO2023079528A1 (en)	2021-11-05	2023-05-11	King Abdullah University Of Science And Technology	Compositions suitable for use in a method for eliciting cross-protective immunity against coronaviruses
CA3255112A1 (en)	2022-03-23	2023-09-28	Nanovation Therapeutics Inc.	HIGH STEROL LIPID NANOPARTICLES
CN119654166A (zh)	2022-04-01	2025-03-18	内诺维什疗法股份有限公司	mRNA递送方法及其组合物
KR20250038747A (ko)	2022-07-22	2025-03-19	인스티튜트 내셔날 드 라 싼테 에 드 라 리셰르셰 메디칼르	만성 폐쇄성 폐질환의 치료를 위한 보르데텔라 균주의 용도
WO2024130009A1 (en)	2022-12-14	2024-06-20	Yale University	Compositions and methods of use thereof for the treatment of virally driven cancers

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1502774A (en) *	1974-06-25	1978-03-01	Nat Res Dev	Immunological preparations
US4148876A (en) *	1975-09-29	1979-04-10	Burroughs Wellcome Co.	Biological preparations
US4201767A (en) *	1978-11-08	1980-05-06	Merck & Co., Inc.	Viral liposome particle
US4522811A (en) *	1982-07-08	1985-06-11	Syntex (U.S.A.) Inc.	Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4721612A (en) *	1984-04-12	1988-01-26	The Liposome Company, Inc.	Steroidal liposomes
US4891208A (en) *	1985-04-10	1990-01-02	The Liposome Company, Inc.	Steroidal liposomes
JPH0688911B2 (ja) *	1985-06-06	1994-11-09	国立予防衛生研究所長	インフルエンザワクチン及びその製造方法

1989
- 1989-08-24 AU AU41861/89A patent/AU627226B2/en not_active Ceased
- 1989-08-24 NZ NZ230423A patent/NZ230423A/en unknown
- 1989-08-24 JP JP1509162A patent/JPH04500203A/ja active Pending
- 1989-08-24 AU AU42214/89A patent/AU631377B2/en not_active Ceased
- 1989-08-24 NZ NZ241926A patent/NZ241926A/xx unknown
- 1989-08-25 DE DE68921389T patent/DE68921389T2/de not_active Expired - Fee Related
- 1989-08-25 DE DE68929033T patent/DE68929033T2/de not_active Expired - Fee Related
- 1989-08-25 EP EP89402343A patent/EP0356339B1/de not_active Expired - Lifetime
- 1989-08-25 EP EP94201844A patent/EP0626169B1/de not_active Expired - Lifetime
- 1989-08-25 ES ES89402343T patent/ES2069600T3/es not_active Expired - Lifetime
- 1989-08-25 CA CA000609464A patent/CA1337332C/en not_active Expired - Fee Related
- 1989-08-25 AT AT89402343T patent/ATE119037T1/de not_active IP Right Cessation
- 1989-08-25 ES ES94201844T patent/ES2133477T3/es not_active Expired - Lifetime
- 1989-08-25 AT AT94201844T patent/ATE182080T1/de not_active IP Right Cessation
1999
- 1999-09-16 GR GR990402336T patent/GR3031244T3/el unknown

Also Published As

Publication number	Publication date
AU4186189A (en)	1990-03-23
CA1337332C (en)	1995-10-17
EP0356339B1 (de)	1995-03-01
GR3031244T3 (en)	1999-12-31
ES2133477T3 (es)	1999-09-16
AU627226B2 (en)	1992-08-20
ES2069600T3 (es)	1995-05-16
DE68929033D1 (de)	1999-08-19
JPH04500203A (ja)	1992-01-16
DE68921389D1 (de)	1995-04-06
DE68921389T2 (de)	1995-06-29
NZ230423A (en)	1993-08-26
AU631377B2 (en)	1992-11-26
EP0356339A1 (de)	1990-02-28
EP0626169A3 (de)	1995-12-13
ATE119037T1 (de)	1995-03-15
DE68929033T2 (de)	1999-12-30
EP0626169B1 (de)	1999-07-14
NZ241926A (en)	1993-08-26
AU4221489A (en)	1990-03-23
EP0626169A2 (de)	1994-11-30

Legal Events

Date	Code	Title	Description
2006-05-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE68929033D1 (de)	1999-08-19	Dosierungsform die ein Antigen und eine Salzform eines organischen Säurederivats eines Sterols enthält
EP1180938A4 (de)	2005-03-16	Agentien, zusammensetzungen und verfahren zur diagnose und/oder behandlung oder vorbeugung von plaquebildenden erkrankungen
FI860015L (fi)	1986-01-02	Menetelmä rokotteen valmistamiseksi piluksia kantavien nisäkkään kudoksiin tarttuvien bakteerien aiheuttamia tauteja vastaan
DE69332518D1 (de)	2003-01-09	Unterdrückung von autoimmunkrankheiten durch antigene in wartestellung
ES2148799T3 (es)	2000-10-16	Anticuerpos monoclonales neutralizantes contra virus sincitial respiratorio.
AU7752487A (en)	1988-01-29	Immunomodulating compositions and their use
OA08652A (fr)	1988-11-30	Compositions, vaccin et anticorps monoclonaux utiles pour le traitement des affections par le virus HIV et procédés de production de ces anticorps et de diagnostic de la présence de ce virus.
DK0994721T3 (da)	2007-04-02	Nervevækstfaktor som vaccineadjuvans
PT89958A (pt)	1989-11-10	Processo de preparacao de antigenio k5 sulfatado e de fragmentos de antigenio k5 sulfatado, de isolamento de antigenio k5 e preparacao de composicoes farmaceuticas
AU1347688A (en)	1988-09-14	Viral antigen, process for its production, and application in diagnosis and therapy (vaccine)
NL189207C (nl)	1993-02-01	Flavivirus antigeen, werkwijze ter bereiding daarvan, tussenprodukten en werkwijze ter bereiding van een vaccin tegen japanse encefalitis.
GR900100772A (el)	1992-03-20	Μέ?οδος για την παρασκευή φαρμακευτικών σκευασμάτων.
FI874329A7 (fi)	1988-04-11	Menetelmä värittömän, hajultaan ja maultaan neutraalin kassia-siemenvalkuaisjauhon valmistamiseksi.
FI875015A0 (fi)	1987-11-13	Vaccin mot juverinflammation.
NO863460D0 (no)	1986-08-28	Fremgangsmaate til fremstilling av 6-fenoksymetyl-4-hydroksy-tetrahydropyran-2-on, fremgangsmaate til deres fremstilling, og deres anvendelse som legemiddel, farmasoeytiske preparater og mellomprodukter.
DK325289D0 (da)	1989-06-29	Strontiumsalt, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende saltet
DK76191D0 (da)	1991-04-25	Filamentoest haemagglutinin fra b.pertussis
ATE244011T1 (de)	2003-07-15	Unterdrückung der thromboxanspiegel durch perkutane verabreichung von aspirin
HUP9801917A2 (hu)	1998-11-30	Immunogén készítmény, eljárás annak előállítására és vakcinaként történő alkalmazására
MacDonald et al.	2010	Efficacy of a single dose hepatitis B depot vaccine
FR2620333B1 (fr)	1990-01-05	Liposomes, leur procede de preparation et application desdits liposomes comme vecteur de produits
GB1212886A (en)	1970-11-18	Equine vaccine and vaccination treatment
FR2382237A1 (fr)	1978-09-29	Nouvelles preparations de serum sanguin a base de mercaptans, leur procede de preparation et medicament les contenant
SU556809A1 (ru)	1977-05-05	Способ получени антител к австралийскому антигену
NO910266L (no)	1991-03-20	Nye 6-methyl-19-nor-steroider, fremgangsmaate for fremstilling av disse, farmasoeytiske preparater inneholdende disse, og deres omdannelse til 17alfa-substituerte 19-nor-pregnadiener.